Published on 1 Jun 2016
Laurent Levy, chief executive of Nanobiotix SA (EPA:NANO), says branching out into immuno-oncology is a “very logical step” in the development of NBTXR3.
In layman’s terms, Nanobiotix’s nano-particles may have the ability to turn a cold tumour ‘hot’, triggering immunogenic cell death.
The company’s radical new approach to radiotherapy, is unearthing some of the most promising new treatments for the killer disease, using the body’s own immune system to attack tumours and mutated cells.
“We see that radiotherapy is taking more and more space into the immuno-oncology field, so that is why we have started to see if NBTXR3 could bring something else, and that’s what we think we have done,” he says.